Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nikoulina, S. E.
Right arrow Articles by Henry, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nikoulina, S. E.
Right arrow Articles by Henry, R. R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:2190-2198, 2002
© 2002 by the American Diabetes Association, Inc.

Inhibition of Glycogen Synthase Kinase 3 Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle

Svetlana E. Nikoulina1,2, Theodore P. Ciaraldi1,2, Sunder Mudaliar1,2, Leslie Carter1,2, Kirk Johnson3, and Robert R. Henry1,2

1 Veterans Affairs San Diego Healthcare System, La Jolla, California
2 Department of Medicine, University of California, San Diego, La Jolla, California
3 Chiron Corporation, Emeryville, California

Glycogen synthase kinase (GSK)-3 has been implicated in the regulation of multiple cellular physiological processes in skeletal muscle. Selective cell-permeable reversible inhibitors (INHs) of GSK-3 (CT98014 and CHIR98023 [Chiron, Emeryville, CA] and LiCl) were used to evaluate the role of GSK-3 in controlling glucose metabolism. Acute treatment (30 min) of cultured human skeletal muscle cells with either INH resulted in a dose-dependent activation of glycogen synthase (GS) with a maximally effective concentration of ~2 µmol/l. The maximal acute effect of either INH on GS (103 ± 25% stimulation over basal) was greater than the maximal insulin response (48 ± 9%, P < 0.05 vs. INH); LiCl was as effective as insulin. The GSK-3 inhibitor effect, like that of insulin, was on the activation state (fractional velocity [FV]) of GS. Cotreatment of muscle cells with submaximal doses of INH and insulin resulted in an additive effect on GS FV (103 ± 10% stimulation, P < 0.05 vs. either agent alone). Glucose incorporation into glycogen was also acutely stimulated by INH. While prolonged (6–24 h) insulin exposure led to desensitization of GS, INH continued to activate GS FV for at least 24 h. Insulin and LiCl acutely activated glucose uptake, whereas INH stimulation of glucose uptake required more prolonged exposure, starting at 6 h and continuing to 24 h. Chronic (4-day) treatment with INH increased both basal (154 ± 32% of control) and insulin-stimulated (219 ± 74%) glucose uptake. Upregulation of uptake activity occurred without any change in total cellular GLUT1 or GLUT4 protein content. Yet the same chronic treatment resulted in a 65 ± 6% decrease in GSK-3 protein and a parallel decrease (61 ± 11%) in GSK-3 total activity. Together with the INH-induced increase in insulin-stimulated glucose uptake, there was an ~3.5-fold increase (P < 0.05) in insulin receptor substrate (IRS)-1 protein abundance. Despite upregulation of IRS-1, maximal insulin stimulation of Akt phosphorylation was unaltered by INH treatment. The results suggest that selective inhibition of GSK-3 has an impact on both GS and glucose uptake, including effects on insulin action, using mechanisms that differ from and are additive to those of insulin.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
A. Moh, W. Zhang, S. Yu, J. Wang, X. Xu, J. Li, and X.-Y. Fu
STAT3 Sensitizes Insulin Signaling by Negatively Regulating Glycogen Synthase Kinase-3{beta}
Diabetes, May 1, 2008; 57(5): 1227 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. P. Ciaraldi, S. E. Nikoulina, R. A. Bandukwala, L. Carter, and R. R. Henry
Role of Glycogen Synthase Kinase-3{alpha} in Insulin Action in Cultured Human Skeletal Muscle Cells
Endocrinology, September 1, 2007; 148(9): 4393 - 4399.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
T. P. Ciaraldi, D. K. Oh, L. Christiansen, S. E. Nikoulina, A. P. S. Kong, S. Baxi, S. Mudaliar, and R. R. Henry
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E891 - E898.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. B. Dokken and E. J. Henriksen
Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats
Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E207 - E213.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
O. Kaidanovich-Beilin and H. Eldar-Finkelman
Long-Term Treatment with Novel Glycogen Synthase Kinase-3 Inhibitor Improves Glucose Homeostasis in ob/ob Mice: Molecular Characterization in Liver and Muscle
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 17 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. B. Dokken, J. A. Sloniger, and E. J. Henriksen
Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle
Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1188 - E1194.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. MacAulay, A. S. Blair, E. Hajduch, T. Terashima, O. Baba, C. Sutherland, and H. S. Hundal
Constitutive Activation of GSK3 Down-regulates Glycogen Synthase Abundance and Glycogen Deposition in Rat Skeletal Muscle Cells
J. Biol. Chem., March 11, 2005; 280(10): 9509 - 9518.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Liberman and H. Eldar-Finkelman
Serine 332 Phosphorylation of Insulin Receptor Substrate-1 by Glycogen Synthase Kinase-3 Attenuates Insulin Signaling
J. Biol. Chem., February 11, 2005; 280(6): 4422 - 4428.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. Bouche, S. Serdy, C. R. Kahn, and A. B. Goldfine
The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes
Endocr. Rev., October 1, 2004; 25(5): 807 - 830.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. M. Wheatley, S. Rattigan, S. M. Richards, E. J. Barrett, and M. G. Clark
Skeletal muscle contraction stimulates capillary recruitment and glucose uptake in insulin-resistant obese Zucker rats
Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E804 - E809.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. V. Skurat and A. D. Dietrich
Phosphorylation of Ser640 in Muscle Glycogen Synthase by DYRK Family Protein Kinases
J. Biol. Chem., January 23, 2004; 279(4): 2490 - 2498.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. Vecchione, A. Aretini, A. Maffei, G. Marino, G. Selvetella, R. Poulet, V. Trimarco, G. Frati, and G. Lembo
Cooperation Between Insulin and Leptin in the Modulation of Vascular Tone
Hypertension, August 1, 2003; 42(2): 166 - 170.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. Plotkin, O. Kaidanovich, I. Talior, and H. Eldar-Finkelman
Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 974 - 980.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
E. J. Henriksen, T. R. Kinnick, M. K. Teachey, M. P. O'Keefe, D. Ring, K. W. Johnson, and S. D. Harrison
Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats
Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E892 - E900.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. B. Ring, K. W. Johnson, E. J. Henriksen, J. M. Nuss, D. Goff, T. R. Kinnick, S. T. Ma, J. W. Reeder, I. Samuels, T. Slabiak, et al.
Selective Glycogen Synthase Kinase 3 Inhibitors Potentiate Insulin Activation of Glucose Transport and Utilization In Vitro and In Vivo
Diabetes, March 1, 2003; 52(3): 588 - 595.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.